Ceftin (Cefuroxime Axetil): Clinical Overview
Ceftin (cefuroxime axetil) is a second-generation oral cephalosporin indicated for respiratory tract infections, sinusitis, otitis media, urinary tract infections, skin/soft tissue infections, and early Lyme disease, with dosing of 250-500 mg twice daily in adults and 20-30 mg/kg/day divided twice daily in children.
Indications and Appropriate Use
Respiratory Tract Infections
For community-acquired pneumonia in children, cefuroxime is listed as an alternative oral agent for step-down therapy or mild infections 1. The 2011 PIDS/IDSA guidelines specifically include cefuroxime among second- or third-generation cephalosporins as alternatives to amoxicillin for pneumococcal pneumonia with penicillin MICs >2.0 μg/mL 1.
For sinusitis, cefuroxime 7.5 mg/kg twice daily (pediatric) or 250-500 mg twice daily (adult) is an appropriate choice 2. The 2005 sinusitis guidelines list cefuroxime among commonly used antibiotics, noting it provides better coverage for H. influenzae than first-generation cephalosporins 2.
Lyme Disease
For early Lyme disease in children unable to tolerate amoxicillin or doxycycline, cefuroxime axetil 30 mg/kg/day (maximum 500 mg per dose) twice daily for 20 days is effective 3, 4. The IDSA guidelines list cefuroxime axetil 500 mg twice daily as a preferred oral regimen for adults 3. A pediatric study demonstrated 87-92% resolution of erythema migrans with cefuroxime compared to 67% with amoxicillin, though all patients had good long-term outcomes 4.
Intra-abdominal Infections
For mild to moderately severe intra-abdominal infections, cefuroxime combined with metronidazole is an acceptable regimen 5, 6. The 2010 SIS/IDSA guidelines recommend a cephalosporin (including cefuroxime) with metronidazole as combination therapy 5. However, the 2024 WHO guidelines favor ceftriaxone over cefuroxime due to broader Gram-negative coverage 6.
Urinary Tract Infections
For pediatric febrile infants 29-60 days old with UTI, ceftriaxone is preferred over cefuroxime 7. Cefuroxime is not specifically recommended in the 2021 AAP febrile infant guidelines 7.
Dosing Regimens
Adults
- Respiratory infections: 250-500 mg twice daily for 5-10 days 2, 8
- Sinusitis: 250-500 mg twice daily 2
- Lyme disease: 500 mg twice daily for 20 days 3
- Uncomplicated gonorrhea: 1000 mg single dose 9
Children
- General infections: 20-30 mg/kg/day divided twice daily (maximum 500 mg per dose) 2, 8, 4
- Sinusitis: 7.5 mg/kg twice daily 2
- Pneumonia: 30 mg/kg/day divided three times daily (IV) or 20-30 mg/kg/day divided twice daily (oral) 8
- Lyme disease: 30 mg/kg/day divided twice daily for 20 days 4
Cefuroxime may be taken without regard to meals, though food increases bioavailability of the suspension formulation 10, 11.
Pharmacokinetic Considerations
The oral suspension has 120% bioavailability relative to capsules 10. Peak plasma concentrations occur 2-4 hours post-dose 10. The drug is 60-70% protein-bound with a half-life of approximately 1.7 hours 10.
For probability of target attainment (PTA ≥90%), tablet doses of 250 mg and 500 mg twice daily achieve adequate time above MIC for pathogens with MICs up to 0.25 and 0.5 mg/L respectively 12. The suspension formulation covers MICs up to 1.0 mg/L 12.
Contraindications and Precautions
Cefuroxime is contraindicated in patients with hypersensitivity to cephalosporins 9. Use caution in patients with severe penicillin allergy due to potential cross-reactivity.
Avoid in pregnant women only if doxycycline would otherwise be indicated (as doxycycline is contraindicated in pregnancy) 3. Otherwise, cefuroxime can be used in pregnancy for appropriate indications 3.
Adverse Effects
Adverse events are generally mild and transient, primarily gastrointestinal disturbances 11, 13, 9. In pediatric studies, mild reactions including oral thrush, diarrhea, or diaper dermatitis occurred in approximately 25% of children, but rarely required discontinuation 14.
One case of Clostridium difficile-associated diarrhea was reported in a pediatric Lyme disease trial 4. Hypersensitivity reactions are uncommon but can occur 14.
Clinical Efficacy Evidence
Multiple randomized controlled trials demonstrate cefuroxime axetil has similar efficacy to amoxicillin/clavulanate, other cephalosporins, quinolones, and macrolides for respiratory tract infections 11, 13. Five-day courses are as effective as 10-day courses for acute otitis media and acute bronchitis 13.
Sequential IV-to-oral therapy with cefuroxime (IV cefuroxime 750 mg 2-3 times daily for 2-5 days followed by oral cefuroxime axetil 500 mg twice daily) is effective for community-acquired pneumonia 11, 13.
Key Clinical Pearls
- Cefuroxime provides better coverage than first-generation cephalosporins for β-lactamase-producing H. influenzae and M. catarrhalis 2, 13
- It is active against penicillin-susceptible and intermediate-resistant S. pneumoniae, but not highly resistant strains 13
- The twice-daily dosing schedule improves adherence compared to more frequent dosing regimens 11
- Cefuroxime is NOT effective against methicillin-resistant Staphylococcus aureus, Pseudomonas aeruginosa, or enterococci 13